NZ508325A - Microemulsion preconcentrates for oral administration containing a piperidine substance P antagonist - Google Patents
Microemulsion preconcentrates for oral administration containing a piperidine substance P antagonistInfo
- Publication number
- NZ508325A NZ508325A NZ508325A NZ50832599A NZ508325A NZ 508325 A NZ508325 A NZ 508325A NZ 508325 A NZ508325 A NZ 508325A NZ 50832599 A NZ50832599 A NZ 50832599A NZ 508325 A NZ508325 A NZ 508325A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antagonist
- oral administration
- piperidine substance
- administration containing
- piperidine
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title abstract 6
- 239000003890 substance P antagonist Substances 0.000 title abstract 3
- 239000004530 micro-emulsion Substances 0.000 title abstract 2
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- NXLUTEDAEFXMQR-BJKOFHAPSA-N n-[(2r,4s)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-chlorophenyl)methyl]piperidin-4-yl]quinoline-4-carboxamide Chemical group FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2[C@@H](C[C@H](CC2)NC(=O)C=2C3=CC=CC=C3N=CC=2)CC=2C=CC(Cl)=CC=2)=C1 NXLUTEDAEFXMQR-BJKOFHAPSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9811200.6A GB9811200D0 (en) | 1998-05-26 | 1998-05-26 | Organic compounds |
| GBGB9818105.0A GB9818105D0 (en) | 1998-08-19 | 1998-08-19 | Organic compounds |
| PCT/EP1999/003623 WO1999061025A1 (en) | 1998-05-26 | 1999-05-26 | Microemulsion preconcentrates containing a piperidine substance p antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ508325A true NZ508325A (en) | 2003-06-30 |
Family
ID=26313736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ508325A NZ508325A (en) | 1998-05-26 | 1999-05-26 | Microemulsion preconcentrates for oral administration containing a piperidine substance P antagonist |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20020156099A1 (https=) |
| EP (1) | EP1082119B1 (https=) |
| JP (1) | JP4083985B2 (https=) |
| KR (1) | KR20010043669A (https=) |
| CN (1) | CN1270714C (https=) |
| AR (1) | AR018376A1 (https=) |
| AT (1) | ATE257380T1 (https=) |
| AU (1) | AU755134B2 (https=) |
| BE (1) | BE1012143A5 (https=) |
| BR (1) | BR9910696A (https=) |
| CA (1) | CA2333154C (https=) |
| DE (2) | DE69914077T2 (https=) |
| DK (1) | DK1082119T3 (https=) |
| ES (1) | ES2214859T3 (https=) |
| FR (1) | FR2779145B1 (https=) |
| GB (1) | GB2353473A (https=) |
| HU (1) | HUP0102202A3 (https=) |
| ID (1) | ID27096A (https=) |
| IL (1) | IL139501A0 (https=) |
| IT (1) | IT1313551B1 (https=) |
| NO (1) | NO20005920L (https=) |
| NZ (1) | NZ508325A (https=) |
| PE (1) | PE20000537A1 (https=) |
| PL (1) | PL344245A1 (https=) |
| PT (1) | PT1082119E (https=) |
| RU (1) | RU2240121C2 (https=) |
| SK (1) | SK17752000A3 (https=) |
| TR (1) | TR200003502T2 (https=) |
| TW (1) | TW537894B (https=) |
| WO (1) | WO1999061025A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR018376A1 (es) | 1998-05-26 | 2001-11-14 | Novartis Ag | Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento |
| US7202282B2 (en) * | 2002-04-22 | 2007-04-10 | University Of Florida | Microemulsions for selective molecular separation |
| GB0220953D0 (en) * | 2002-09-10 | 2002-10-23 | Novartis Ag | Organic compounds |
| US7842791B2 (en) | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
| FR2935001B1 (fr) * | 2008-08-14 | 2011-12-30 | Commissariat Energie Atomique | Emulsion fluorescente |
| FR2934954B1 (fr) | 2008-08-14 | 2011-07-22 | Commissariat Energie Atomique | Emulsion fluorescente de vert d'indocyanine |
| FR2934955B1 (fr) | 2008-08-14 | 2011-07-08 | Commissariat Energie Atomique | Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions |
| FR2934953B1 (fr) | 2008-08-14 | 2011-01-21 | Commissariat Energie Atomique | Nanoemulsions de nanocristaux |
| WO2014106048A2 (en) * | 2012-12-31 | 2014-07-03 | Jrx Biotechnology, Inc. | Liquid topical pharmaceutical nano-emulsion formulations |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3305689A1 (de) | 1983-02-18 | 1984-08-23 | Mack Chem Pharm | Pharmazeutische zubereitung mit retardwirkung |
| US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| DE4220616C2 (de) | 1992-06-24 | 1994-12-22 | Byk Gulden Lomberg Chem Fab | Dexniguldipin zur intravenösen Verabreichung |
| EP1142568A1 (en) | 1992-09-25 | 2001-10-10 | Novartis AG | Pharmaceutical compositions containing cyclosporins |
| GB2278780B (en) * | 1993-05-27 | 1998-10-14 | Sandoz Ltd | Macrolide formulations |
| ES2270426T3 (es) * | 1994-03-18 | 2007-04-01 | Supernus Pharmaceuticals, Inc. | Sistema de suministros de farmacos emulsionados. |
| TW397825B (en) * | 1994-10-14 | 2000-07-11 | Novartis Ag | Aroyl-piperidine derivatives |
| GB2308545B (en) | 1994-10-26 | 1999-06-02 | Novartis Ag | Pharmaceutical microemulsion preconcentrates |
| PE52896A1 (es) * | 1994-10-26 | 1996-12-12 | Novartis Ag | Composicion farmaceutica |
| FR2728165A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene |
| FR2728169A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales |
| ATE209204T1 (de) | 1995-03-27 | 2001-12-15 | Hisamitsu Pharmaceutical Co | Piperidinderivate. |
| NZ280689A (en) | 1995-12-15 | 1997-08-22 | Bernard Charles Sherma Sherman | Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol |
| GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| AU2898297A (en) | 1996-05-24 | 1998-01-05 | Novartis Ag | Use of substance p antagonists for treating social phobia |
| AR018376A1 (es) | 1998-05-26 | 2001-11-14 | Novartis Ag | Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento |
-
1999
- 1999-05-24 AR ARP990102454A patent/AR018376A1/es not_active Application Discontinuation
- 1999-05-24 TW TW088108449A patent/TW537894B/zh not_active IP Right Cessation
- 1999-05-25 BE BE9900364A patent/BE1012143A5/fr not_active IP Right Cessation
- 1999-05-25 PE PE1999000436A patent/PE20000537A1/es not_active Application Discontinuation
- 1999-05-26 EP EP99927760A patent/EP1082119B1/en not_active Expired - Lifetime
- 1999-05-26 ID IDW20002316A patent/ID27096A/id unknown
- 1999-05-26 DE DE69914077T patent/DE69914077T2/de not_active Expired - Lifetime
- 1999-05-26 JP JP2000550485A patent/JP4083985B2/ja not_active Expired - Fee Related
- 1999-05-26 HU HU0102202A patent/HUP0102202A3/hu unknown
- 1999-05-26 BR BR9910696-5A patent/BR9910696A/pt not_active Application Discontinuation
- 1999-05-26 WO PCT/EP1999/003623 patent/WO1999061025A1/en not_active Ceased
- 1999-05-26 IT IT1999MI001164A patent/IT1313551B1/it active
- 1999-05-26 NZ NZ508325A patent/NZ508325A/xx unknown
- 1999-05-26 ES ES99927760T patent/ES2214859T3/es not_active Expired - Lifetime
- 1999-05-26 IL IL13950199A patent/IL139501A0/xx unknown
- 1999-05-26 PL PL99344245A patent/PL344245A1/xx unknown
- 1999-05-26 FR FR9906629A patent/FR2779145B1/fr not_active Expired - Fee Related
- 1999-05-26 KR KR1020007012871A patent/KR20010043669A/ko not_active Ceased
- 1999-05-26 PT PT99927760T patent/PT1082119E/pt unknown
- 1999-05-26 CN CNB998066036A patent/CN1270714C/zh not_active Expired - Fee Related
- 1999-05-26 RU RU2000133308/15A patent/RU2240121C2/ru not_active IP Right Cessation
- 1999-05-26 DK DK99927760T patent/DK1082119T3/da active
- 1999-05-26 AU AU45008/99A patent/AU755134B2/en not_active Ceased
- 1999-05-26 SK SK1775-2000A patent/SK17752000A3/sk unknown
- 1999-05-26 DE DE19983247T patent/DE19983247T1/de not_active Withdrawn
- 1999-05-26 CA CA002333154A patent/CA2333154C/en not_active Expired - Fee Related
- 1999-05-26 AT AT99927760T patent/ATE257380T1/de not_active IP Right Cessation
- 1999-05-26 GB GB0028506A patent/GB2353473A/en not_active Withdrawn
- 1999-05-26 TR TR2000/03502T patent/TR200003502T2/xx unknown
-
2000
- 2000-11-23 NO NO20005920A patent/NO20005920L/no not_active Application Discontinuation
-
2002
- 2002-04-10 US US10/119,549 patent/US20020156099A1/en not_active Abandoned
-
2003
- 2003-03-04 US US10/379,345 patent/US6949257B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
| MXPA03006476A (es) | Composiciones farmaceuticas, formas de dosificacion y metodos para administracion oral de epotilonas. | |
| MXPA03009971A (es) | FORMA DE DOSIFICACIoN FARMACEUTICA DE MESILATO DE NELFINAVIR AMORFO. | |
| FR2805818B1 (fr) | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant | |
| NO308296B1 (no) | Indolyl neuropeptid Y reseptorantagonister, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av legemiddel | |
| GEP20063875B (en) | Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist | |
| FR2783246B1 (fr) | Derives d'azetidine, leur preparation et les medicaments les contenant | |
| HUP0203836A3 (en) | 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use | |
| MY112915A (en) | Multiple unit tableted dosage form 1 | |
| ATE274902T1 (de) | Pharmazeutische dosierungsformen zur kontrollierter pulsierender abgabe | |
| FR2797771B1 (fr) | Procede pour tester l'aptitude d'une electrode-reservoir d'ionophorese a delivrer un medicament | |
| DK0503440T3 (da) | Sumatriptanholdige lægemidler | |
| AU2003295614A8 (en) | Delivery of pharmaceutical agents via the human insulin receptor | |
| HUP0303258A3 (en) | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists and pharmaceutical compositions containing them | |
| HUP0103558A3 (en) | Pharmaceutical composition containing nmda receptor antagonist for the treatment of stroke and traumatic brain insury | |
| HUP0303081A3 (en) | Thrombin receptor antagonists, pharmaceutical compositions containing them and their use | |
| HUP0400349A3 (en) | Ccr5 antagonists useful for treating aids and pharmaceutical compositions containing them | |
| NZ508325A (en) | Microemulsion preconcentrates for oral administration containing a piperidine substance P antagonist | |
| MXPA04001848A (es) | Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson. | |
| AU2003243439A8 (en) | Medical device for intra-lumenal delivery of pharmaceutical agents | |
| NZ502495A (en) | Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome | |
| RU2002122084A (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств | |
| PL350568A1 (en) | N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors | |
| BG106548A (en) | Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog | |
| SE9903995D0 (sv) | New combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |